US Patent 8,298,556: Scope, Claims, Expiration, Orange Book Status and Deoxycholic Acid Patent Landscape

US Patent 8,298,556 protects injectable, non-liposuction treatment of localized fat using deoxycholate or deoxycholic acid at specified concentrations, without phosphatidylcholine as an active ingredient. Its strongest commercial relevance is to deoxycholic-acid injectable products such as KYBELLA. The patent does not broadly cover every use of deoxycholic acid. Infringement generally requires the claimed concentration range, localized-fat indication, pharmaceutical excipient, and absence of phosphatidylcholine as an active ingredient.

The patent issued October 30, 2012, from the Kythera deoxycholate development program. Its expected patent-term expiration is in September 2027, subject to the official USPTO patent-term calculation and any applicable adjustment. The patent is distinct from later formulation, dosing, and manufacturing patents that may provide additional protection for commercial deoxycholic-acid products.

What does US Patent 8,298,556 protect?

US 8,298,556, titled “Methods and compositions for treating fat,” claims methods for treating unwanted localized fat accumulation with a deoxycholate salt or deoxycholic acid composition. The central limitations are:

Claim element	Scope
Therapeutic objective	Treating, dissolving, or reducing unwanted localized fat
Procedure	Non-liposuction treatment; several claims expressly require injection
Active substance	Deoxycholate salt or deoxycholic acid
Concentration	About 0.5%, 1%, 2.5%, or 5% weight/volume
Formulation	Pharmaceutically acceptable excipient; certain claims require an aqueous composition
Excluded active ingredient	Phosphatidylcholine cannot be present as an active ingredient
Preferred salt	Sodium deoxycholate
Target	Localized fat accumulation, adipose tissue, or fat deposits
Additional agents	Anti-inflammatory agents, analgesics, hyaluronidase, or collagenase may be included under claim 11

The patent is primarily a method-of-treatment patent. It is not a broad composition-of-matter patent covering deoxycholic acid in all forms or all therapeutic uses.

How do the individual claims of US 8,298,556 differ?

Claims 1 through 4: non-liposuction treatment

Claim 1 is the broadest independent claim in the patent. It covers contacting unwanted localized fat accumulation with a composition containing a deoxycholate salt and a pharmaceutically acceptable excipient at one of four specified concentrations.

Claim 1 does not expressly require injection. “Contacting” can encompass injection, provided the other limitations are met. The claim is limited by:

A subject who has and desires removal of localized fat.
A non-liposuction method.
A deoxycholate salt.
One of the recited concentration levels.
A pharmaceutically acceptable excipient.
No phosphatidylcholine used as an active ingredient.

Claim 2 narrows the active ingredient to sodium deoxycholate. Claim 3 limits the target to adipose tissue. Claim 4 limits the excipient to water, a buffer, benzyl alcohol, or combinations of those materials.

Claim 5: injected aqueous deoxycholate composition

Claim 5 requires injection into the unwanted localized fat. It also requires an aqueous composition. This claim is commercially significant because it aligns more closely with an injectable aesthetic product than claim 1.

The claim remains limited to the four listed concentration levels. A competing product using a materially different concentration could avoid literal infringement, although the interpretation of “about” may create a range around each stated concentration.

Claim 6: sodium deoxycholate with a closed excipient group

Claim 6 is narrower because the composition consists of sodium deoxycholate and an excipient selected from water, a buffer, benzyl alcohol, or combinations of those materials.

The use of “consisting of” creates a closed-composition issue. A product containing additional active or inactive ingredients may fall outside the literal scope of claim 6, depending on whether the additional ingredient materially changes the claimed composition or is considered an incidental component.

Claim 6 also requires:

Injection into the fat deposit.
Sodium deoxycholate.
One of the four listed concentrations.
No phosphatidylcholine.
No excipient outside the listed group, subject to claim construction.

Claims 7 through 10: deoxycholic acid formulations

Claim 7 uses “deoxycholic acid” rather than “deoxycholate salt.” Claim 8 narrows the claim to a sodium salt of deoxycholic acid. The apparent overlap between claims 1 and 7 gives the patent coverage over both salt-based and acid-described formulations.

Claim 9 limits the target to adipose tissue. Claim 10 limits the excipient in claims 5, 7, or 8 to water, a buffer, benzyl alcohol, or combinations.

Claim 11: additional therapeutic agents

Claim 11 permits at least one additional agent selected from:

An anti-inflammatory agent.
An analgesic agent.
Hyaluronidase.
Collagenase.

This claim does not eliminate the core limitations of the underlying claims. A product containing one of these agents still must satisfy the applicable deoxycholate, concentration, injection or treatment, excipient, and phosphatidylcholine limitations.

What concentrations are covered by US 8,298,556?

The patent expressly identifies four concentration points:

Stated concentration	Weight/volume interpretation
0.5%	Approximately 5 mg/mL
1%	Approximately 10 mg/mL
2.5%	Approximately 25 mg/mL
5%	Approximately 50 mg/mL

The claims use “about,” which may extend coverage beyond the exact numerical points. The legal scope depends on intrinsic evidence, prosecution history, specification support, and expert evidence concerning formulation tolerances and clinical relevance.

A product at 10 mg/mL is the most obvious concentration overlap for a commercial deoxycholic-acid injectable. A product at 20 mg/mL, 30 mg/mL, or another concentration would require a separate analysis of whether it falls within the construction of “about” 1% or 2.5%, or whether a doctrine-of-equivalents argument is available.

What formulations are protected by US Patent 8,298,556?

The patent covers relatively simple aqueous formulations containing deoxycholate or deoxycholic acid and a pharmaceutically acceptable excipient. The expressly identified excipients are:

Water.
A buffer.
Benzyl alcohol.
Combinations of those materials.

The claims exclude phosphatidylcholine only when it is used as an active ingredient. That distinction matters. A formulation containing trace phosphatidylcholine as an impurity, inactive processing residue, or excipient may present a different issue from a formulation marketed as a combination of phosphatidylcholine and deoxycholate for fat reduction.

The patent does not require a particular pH, injection volume, needle size, dosing schedule, injection site, treatment interval, or number of treatment sessions in the quoted claims. Those limitations may appear in the specification or related patents, but they are not required by claims 1 through 11 as provided.

When does US Patent 8,298,556 lose exclusivity?

The expected expiration date is in September 2027, based on the patent’s underlying filing and priority record. The controlling term is the official USPTO term calculation, not the 20-year period measured from the provisional filing date.

Event	Date or period
Earliest development priority	September 2006 provisional period
Nonprovisional patent filing	September 2007 period
Patent issued	October 30, 2012
Expected ordinary patent expiration	September 2027
FDA new chemical entity exclusivity for KYBELLA	Expired in 2020
Earliest ordinary generic entry	Potentially before patent expiry only if patents are successfully challenged, settled, licensed, or otherwise avoided

FDA regulatory exclusivity and patent exclusivity are separate. KYBELLA’s five-year new chemical entity exclusivity expired before the principal method patent. A generic or follow-on applicant must still address listed patents and any other enforceable patent rights.

What is the Orange Book status of US 8,298,556?

US 8,298,556 is associated with the KYBELLA deoxycholic-acid product and has been treated as an Orange Book-relevant method patent. Orange Book listing depends on the approved product, the patent claims, the applicable use code, and the FDA’s listing record for the relevant edition of the Approved Drug Products with Therapeutic Equivalence Evaluations.

For an ANDA applicant, a listed method patent can generate a Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable, or not infringed. A Paragraph III certification would defer approval until patent expiration. A section viii statement may be available only if the proposed labeling can omit the patented use.

Because the claims expressly target localized fat reduction, a competing injectable product marketed for the same aesthetic indication would face greater Orange Book and induced-infringement risk than a product labeled for an unrelated indication.

What Paragraph IV challenges could target this patent?

A Paragraph IV challenge to US 8,298,556 could focus on claim construction, validity, or noninfringement.

Potential noninfringement theories

A generic or competing product could argue that:

Its concentration does not fall within “about” 0.5%, 1%, 2.5%, or 5%.
Its product does not contain a deoxycholate salt or deoxycholic acid in the claimed form.
It is not labeled or marketed for localized fat removal.
The product does not require injection into fat or adipose tissue.
Phosphatidylcholine is an active ingredient, placing the product outside the claims.
The formulation uses excipients outside the closed group in claim 6.
The product is not used in a non-liposuction method.

Potential validity theories

Potential invalidity arguments may include:

Lack of written description for the full concentration and formulation scope.
Lack of enablement across all claimed deoxycholate salts, concentrations, excipients, and treatment methods.
Anticipation by earlier deoxycholate or phosphatidylcholine fat-reduction disclosures.
Obviousness based on known detergent effects of bile salts and prior injection techniques.
Indefiniteness involving “about,” “unwanted,” “localized,” or “having and desiring removal.”
Double-patenting issues involving related Kythera patent families.

The strongest validity analysis would depend on the full prosecution history and the prior art that was before the examiner. The claim language alone does not establish whether a particular invalidity defense would succeed.

Which companies are challenging deoxycholic-acid patent protection?

The principal commercial exposure is associated with generic manufacturers seeking to enter the deoxycholic-acid injectable market after filing an ANDA referencing KYBELLA. Public patent disputes in this area have involved AbbVie and its affiliates following AbbVie’s acquisition of Allergan, which previously acquired Kythera.

A complete company-by-company Paragraph IV table requires the relevant FDA litigation records, ANDA notices, district-court dockets, and current Orange Book data. The patent number alone does not establish that a particular generic has filed a Paragraph IV certification or that litigation is pending.

The commercial challengers most likely to be relevant are manufacturers with sterile injectable capability and experience in dermatology, aesthetic medicine, or ANDA products. The manufacturing burden is higher than for an ordinary oral generic because the product requires sterile production, validated filling, injectable stability, container-closure controls, and clinical or analytical bridging acceptable to FDA.

What patent litigation affects US 8,298,556?

The relevant litigation risk has three layers:

Patent litigation over US 8,298,556.
Litigation over later KYBELLA formulation, dosing, or use patents.
Regulatory litigation or patent-listing disputes concerning Orange Book eligibility and use codes.

A Paragraph IV notice typically creates a 45-day period for the patent owner to sue and potentially obtain a 30-month stay of ANDA approval under the Hatch-Waxman framework. The stay does not automatically extend the patent term. It delays FDA approval while litigation proceeds, subject to statutory exceptions and court rulings.

A settlement could provide an authorized generic, a delayed entry date, a license, or other market-access terms. Settlement terms are often confidential, and a court docket may disclose only the existence of the agreement or the date of dismissal.

How strong is the patent estate for KYBELLA compared with US 8,298,556?

US 8,298,556 has meaningful but limited scope. Its commercial strength comes from the combination of method, concentration, injection, and no-phosphatidylcholine limitations. Its main weaknesses are that:

It is not a composition-of-matter patent.
It does not cover every deoxycholic-acid use.
The four concentration points create design-around opportunities.
“About” can create both infringement uncertainty and indefiniteness arguments.
A non-aesthetic indication may reduce direct label overlap.
A non-injectable product may avoid claims 5, 6, and 7.

The broader KYBELLA patent estate may include later patents directed to formulation characteristics, dosing regimens, administration techniques, manufacturing, or particular treatment sites. Those later patents can maintain litigation leverage even if a competitor avoids claim 1 or obtains a judgment against this patent.

Protection category	Relevance to US 8,298,556
Active ingredient	Limited; no broad deoxycholic-acid composition claim
Localized-fat treatment	Strongly covered if other limitations are met
Injection	Expressly covered in claims 5 through 8
Concentration	Four specified concentration levels
Formulation	Water, buffers, benzyl alcohol, and combinations
Phosphatidylcholine combination	Excluded when used as an active ingredient
Manufacturing process	Not covered by the quoted claims
Dosing schedule	Not expressly required by the quoted claims
Geographic reach	United States only

What generic launch scenarios exist?

Scenario 1: Launch after patent expiration

A generic applicant waits until the expected September 2027 expiration date and obtains FDA approval without prevailing in Paragraph IV litigation. This is the lowest litigation-risk scenario.

Scenario 2: Early launch after a successful challenge

The applicant proves invalidity, unenforceability, or noninfringement and receives approval before expiration. The applicant must also clear any later-listed patents.

Scenario 3: Settlement-based entry

The generic obtains a licensed entry date before or after September 2027. The agreement may include supply, authorized-generic, or commercial restrictions.

Scenario 4: Label carve-out

The applicant removes the localized-fat indication from its labeling. This strategy is difficult if the product’s commercial identity is tied to aesthetic fat reduction, and it may not eliminate induced-infringement exposure if the manufacturer promotes the patented use outside the label.

Scenario 5: Formulation or concentration design-around

A competitor uses a different concentration, active form, excipient system, indication, or administration route. This approach must be assessed against both literal infringement and the doctrine of equivalents, as well as later patents in the KYBELLA estate.

What manufacturing and intellectual-property barriers remain?

The primary technical barrier is sterile injectable manufacturing. A competing product must control:

Deoxycholic-acid identity and purity.
Salt formation and pH.
Osmolality and injection tolerability.
Particulate and endotoxin levels.
Sterility assurance.
Container-closure integrity.
Stability over the proposed shelf life.
Consistency of concentration across lots.

The patent’s simple excipient language does not eliminate regulatory complexity. FDA may require comparative analytical data, formulation characterization, manufacturing controls, and clinical support for an injectable product.

The main IP barriers are cumulative. A challenger that avoids US 8,298,556 may still face later formulation or use patents. Conversely, a patent owner that relies only on this patent has limited protection against a product outside the specified concentration and indication framework.

What is the revenue exposure from US 8,298,556?

The patent protects a principal commercial use of KYBELLA: injection-based reduction of submental fat and other localized fat deposits. Its economic value therefore depends on:

KYBELLA sales before generic entry.
The share of sales tied to the localized-fat indication.
The number and scope of later patents.
The timing of any generic or authorized-generic launch.
Physician and patient switching behavior.
Reimbursement, because aesthetic use is frequently cash-pay.
The ability of competitors to obtain a substitutable injectable product.

The patent does not independently protect all revenue associated with deoxycholic acid. Its exposure is concentrated in products that use the claimed active ingredient and concentration for localized-fat reduction.

Key Takeaways

US 8,298,556 is a U.S. method-of-treatment patent for non-liposuction reduction of localized fat with deoxycholate or deoxycholic acid.
The claims center on 0.5%, 1%, 2.5%, and 5% w/v concentrations.
Claims 5 through 8 create direct risk for injectable deoxycholic-acid products.
Sodium deoxycholate is expressly covered.
Water, buffers, benzyl alcohol, and combinations are identified excipients.
Phosphatidylcholine is excluded when used as an active ingredient.
The expected patent expiration is in September 2027.
FDA NCE exclusivity for KYBELLA expired earlier and does not determine patent expiration.
Paragraph IV exposure depends on the Orange Book listing, applicable use code, later KYBELLA patents, and the challenger’s proposed labeling.
The patent is commercially important but not a broad composition-of-matter patent.
Sterile injectable manufacturing and later formulation or dosing patents remain material entry barriers.

FAQs about US Patent 8,298,556 and deoxycholic-acid products

Does US 8,298,556 cover KYBELLA itself?

It covers methods using the claimed deoxycholate or deoxycholic-acid formulation for localized-fat reduction. It is not, by itself, a broad patent covering every physical composition or every use of KYBELLA.

Can a product avoid the patent by using phosphatidylcholine?

The claims exclude phosphatidylcholine when it is used as an active ingredient. A product using phosphatidylcholine does not automatically avoid every related patent, but it may fall outside these specific claims if the exclusion is satisfied.

Does the patent cover treatment of obesity?

The quoted claims target unwanted localized fat accumulation, fat deposits, or adipose tissue. They do not expressly claim systemic obesity treatment or generalized weight loss.

Is a 10 mg/mL product within the patent?

A 10 mg/mL product corresponds approximately to 1% w/v and is a direct concentration match. The product must also satisfy the remaining claim limitations, including the treatment, formulation, administration, and phosphatidylcholine limitations.

Can an injectable deoxycholic-acid product be approved without infringing this patent?

FDA approval and patent noninfringement are separate questions. Approval may be possible, but a product labeled or marketed for localized-fat reduction at a claimed concentration could still face infringement litigation.

References

U.S. Patent No. 8,298,556. (2012). Methods and compositions for treating fat. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (2015). KYBELLA (deoxycholic acid) injection, prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
U.S. Food and Drug Administration. (2015). FDA approves treatment to improve appearance of moderate to severe fat below the chin. FDA.
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. USPTO.
Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j); 35 U.S.C. §§ 156, 271(e).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1758590	⤷ Start Trial	PA2017006	Lithuania	⤷ Start Trial
European Patent Office	1758590	⤷ Start Trial	300907	Netherlands	⤷ Start Trial
European Patent Office	1758590	⤷ Start Trial	CA 2017 00067	Denmark	⤷ Start Trial
European Patent Office	1758590	⤷ Start Trial	LUC00029	Luxembourg	⤷ Start Trial
European Patent Office	1758590	⤷ Start Trial	2017C/063	Belgium	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,298,556

Summary for Patent: 8,298,556